Search Within

MSK Grad Students

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (13)
  3. Research Letter (2)
  4. Review (1)
Groups
  1. CTCR Scholars (43)
  2. Center for Hematologic Malignancies (43)
  3. Department of Medicine (43)
  4. Hematologic Malignancies, Division of (43)
  5. Lymphoma (43)
  6. Master of Science in Clinical and Translational Cancer Research (43)

More Groups

People
  1. Alison Moskowitz (43)
  2. Steven Horwitz (40)
  3. Ariela Noy (35)
  4. Andrew Zelenetz (34)
  5. Anita Kumar (32)
  6. Matthew Matasar (32)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (11)
  5. 2020 (11)
  6. 2019 (10)

More Years

Publications
  1. Blood (22)
  2. Journal of Clinical Oncology (4)
  3. Blood Cancer Journal (3)
  4. Hematological Oncology (3)
  5. Leukemia and Lymphoma (3)
  6. Blood Advances (2)

More Publications

Publishers
  1. American Society of Hematology (24)
  2. American Society of Clinical Oncology (4)
  3. Nature Publishing Group (4)
  4. Taylor & Francis Group (3)
  5. Wiley Blackwell (3)
  6. Elsevier Inc. (1)

More Publishers

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation
    Research Letter

    Stuver, R.; Mian, A.; Brown, S.; Devlin, S.; Caimi, P. F.; Chinapen, S.; Dahi, P.; Dean, R.; Epstein-Peterson, Z. D.; Hill, B.; more...
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience
    Journal Article

    Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save